The letter notes that products were labeled for research use only or not for human consumption. FDA reviewed the website in December 2025.
FDA posted the letter on April 7, 2026. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1
What does the letter say, in brief?
| Company | Lovega LLC dba Pink Pony Peptides |
| Location | Wellington, FL |
| Website named | pinkponypeptides.com |
| Letter dated | March 31, 2026 |
| Posted by FDA | April 7, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| FDA’s subject line | Unapproved New Drugs Sold Over the Internet |
| Drugs named | tirzepatide and retatrutide |
| Kind of letter | Unapproved drugs sold online |
| Reply asked within | fifteen working days |
| Close-out letter | None posted as of November 20, 2026 |
| FDA record | MARCS-CMS 721088 |
What did FDA quote from pinkponypeptides.com?
The letter quotes 4 passages. FDA quotes them as examples and says in most letters that the list is not exhaustive.1
laboratory research purposes only
[n]ot for human consumption,
As a dual GIP and GLP-1 receptor agonist, Tirzepatide helps: o . . . Reduce appetite and increase satiety o . . . Enhance insulin sensitivity and glucose control o . . . Curb cravings without harsh stimulants o . . . Support fat loss over time with clinical precision Originally developed for type 2 diabetes, Tirzepatide has rapidly become a favorite among physicians and wellness experts for its dramatic body recomposition results and long-lasting appetite regulation.
As a GIP, GLP-1, and glucagon receptor agonist, Retatrutide offers three times the fat-fighting horsepower in one clean, clinical ride. This cutting-edge peptide has shown jaw-dropping results in clinical trials — helping the body torch fat, suppress appetite, regulate blood sugar, and even improve metabolic function better than its single-pathway competitors.
Which parts of the law did FDA cite?
The letter cites 2 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.
| Section | What it says | Letters citing it |
|---|---|---|
| 505(a) | A new drug may not be sold across state lines without an approved application | 48 |
| 301(d) | It is prohibited to introduce a drug into interstate commerce in violation of section 505 | 48 |
What did FDA ask the company to do?
In the letter’s own words:
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations.
If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.
FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1
Has FDA warned the seller I use?
Type a seller’s name or website. The search runs over all 164 letters in this database.
How many GLP-1 letters has FDA sent?
70 letters in this database are of the same kind as this one, websites selling drugs that FDA considers unapproved and misbranded. 115 of the 164 letters name tirzepatide. 21 of the 164 letters name retatrutide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.
Which other sellers got a similar letter?
What does an FDA warning letter mean for someone buying from this seller?
FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.
FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.
A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.
What is the full text of the letter?
This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1
Read the full letter (890 words)
March 31, 2026
RE: 721088
Susan Vega:
This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https://pinkponypeptides.com/ in December 2025. The FDA has observed that your website offers “GLP-2 TZ,” “GLP-3 RT,” and “Bacteriostatic Water” (hereinafter Pink Pony Peptides products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.
Despite statements on your product labeling marketing your products for “laboratory research purposes only” and “[n]ot for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body.
Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:
GLP-2 TZ
On the webpage https://pinkponypeptides.com/product/glp2/:
“As a dual GIP and GLP-1 receptor agonist, Tirzepatide helps:
o . . . Reduce appetite and increase satiety
o . . . Enhance insulin sensitivity and glucose control
o . . . Curb cravings without harsh stimulants
o . . . Support fat loss over time with clinical precision
Originally developed for type 2 diabetes, Tirzepatide has rapidly become a favorite among physicians and wellness experts for its dramatic body recomposition results and long-lasting appetite regulation.”
GLP-3 RT
On the webpage https://pinkponypeptides.com/product/glp3/:
“As a GIP, GLP-1, and glucagon receptor agonist, Retatrutide offers three times the fat-fighting horsepower in one clean, clinical ride. This cutting-edge peptide has shown jaw-dropping results in clinical trials — helping the body torch fat, suppress appetite, regulate blood sugar, and even improve metabolic function better than its single-pathway competitors.”
Bacteriostatic Water
Your firm offers “Bacteriostatic Water” for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the two above-mentioned GLP products. The sale of these products together demonstrates that you intend for your “Bacteriostatic Water” to be used in combination for injection. Therefore, your “Bacteriostatic Water” is a drug.
Your Pink Pony Peptides products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
Conclusion
The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.
Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721088” in the subject line of the email.
Sincerely,
/S/
Tina Smith, M.S.
Captain, U.S. Public Health Service
Director
Office of Unapproved Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration
Content current as of:
04/07/2026
Regulated Product(s)
Drugs
Sources
- FDA. Warning letter to Lovega LLC dba Pink Pony Peptides, March 31, 2026 (MARCS-CMS 721088). fda.gov
- FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
- FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider